News - 03 Dec `20FDA Meeting on Vitiligo: New Date

New

UPDATE: FDA is announcing a new date for the meeting. The public meeting will be held on March 8, 2021 from 10 a.m. to 2:30 p.m. EST, in a virtual (online only) format. Please save this date and time if you are interested in attending this public meeting.

US Food and Drug Administration (FDA) is conducting its first public meeting on Patient-Focused Drug Development for Vitiligo. The meeting is intended to allow FDA to obtain patient perspectives on the impact of vitiligo, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment. 

Additional information about the meeting can be found on the meeting webpage. The webpage will be updated as meeting materials are developed, and registration will be available closer to the meeting date.

Please email the PFDD Staff at patientfocused@fda.hhs.gov if you have any questions.

 

      FAQOther Questions

      • Which diseases most commonly accompany vitiligo?

        According to a 10-year study, vitiligo patients have a statistically significant higher prevalence of other autoimmune conditions and dermatological disorders: hypothyroidism...

      • What is vitiligo?

        Vitiligo (pronounced vit-ill-EYE-go) is a relatively common skin disease characterized by smooth, white, painless spots or patches on various parts of the body and hairs above i...

      • Will it spread?

        Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...